Author:
Pennartz C.,Schrader H.,Ritter P.R.,Tannapfel A.,Schmidt W.E.,Meier J.J.
Publisher
Springer Science and Business Media LLC
Reference12 articles.
1. Agnelli G, Gallus A, Goldhaber SZ et al (2007) Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59–7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59–7939 in Patients with Acute Symptomatic Deep- Vein Thrombosis) study. Circulation 116:180–187
2. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery; Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–2429
3. Fuster V, Rydén LE, Cannom DS et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patient with Atrial Fibrillation). Eur Heart J 27:1979–2030
4. Höhler T, Schnütgen M, Helmreich-Becker I et al (1994) Drug-induced hepatitis: a rare complication of oral anticoagulants. J Hepatol 21:447–449
5. Krähenbühl S, Kaplowitz N (1996) Drug-induced hepatotoxicity: clinical presentation. Pathogenesis, risk factors, diagnosis and treatment. In: Schmid R, Bianchi L, Blum HE et al (eds) Acute and chronic liver diseases. Molecular biology and clinics. Kluwer, Dordrecht, p 147–158
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献